The FDA Just Flagged a Major GLP-1 Compounder for Safety Violations. What This Means for Your Treatment.

For anyone using compounded versions of GLP-1 medications like semaglutide or tirzepatide to manage weight or blood sugar, a warning issued by federal health regulators in September 2026 is worth paying close attention to.

The U.S. Food and Drug Administration issued a formal warning letter to Houston-based Empower Pharmacy on September 18, 2026, following an inspection that uncovered a series of significant manufacturing and safety concerns. Empower is one of the largest compounding pharmacies in the United States and has been a major supplier of compounded GLP-1 medications at a time when demand for these drugs has far outpaced the supply of brand-name alternatives.

The FDA's findings were specific and serious. Investigators determined that Empower had been producing what amounted to copies of FDA-approved semaglutide and tirzepatide products on a regular and large-scale basis, which raises questions about compliance with federal compounding exemptions. Beyond that, inspectors cited insanitary conditions and violations of current good manufacturing practice standards.

Among the technical deficiencies documented were failures in smoke studies performed under dynamic conditions, inadequate media fill testing, and deficiencies in aseptic processing, environmental monitoring, quality control, and production procedures. These are not minor paperwork issues. They go to the heart of whether a sterile injectable medication has been prepared safely.

The FDA acknowledged that some of Empower's proposed corrective actions appeared adequate, others were still being evaluated, and others were deemed insufficient. The agency directed the pharmacy to respond within 15 working days and warned that failure to adequately address the violations could result in legal action, including seizure of products and injunction.

For patients currently using compounded semaglutide or tirzepatide sourced from any pharmacy, this development serves as an important reminder of the risks that can come with compounded medications. Unlike FDA-approved drugs, compounded products do not undergo the same premarket review for safety, effectiveness, and manufacturing quality. That does not mean all compounded medications are unsafe, but it does mean that the source and quality standards of the pharmacy matter enormously.

At My Adult Doctor, patient safety is at the center of everything we do. Our prescription pharmacy offers a wide range of physician-prescribed compounded medications across GLP-1 therapy, hormone health, peptides, sexual health, weight management, and more, all prescribed following a clinical consultation with one of our board-certified physicians.

Every prescription is tied to a licensed clinical evaluation, so patients are never navigating their medications without professional guidance. If you have questions about your current GLP-1 medication source or want to explore safe, physician-supervised treatment options, connect with a board-certified physician today.

References / Sources

1. Becker's Hospital Review. FDA Flags Sterility Concerns at Major GLP-1 Compounder. September 23, 2026. BeckersHospitalReview.com.

2. U.S. Food and Drug Administration. Warning Letter: Empower Clinic Services LLC DBA Empower Pharmacy. September 18, 2026. FDA.gov.

3. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov.